Exchange: NASDAQ Sector: Healthcare Industry: Medical Instruments & Supplies
Current Signal: SELL (auto-tracking)
2.29% $6.26
America/New_York / 19 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 250.74 mill |
EPS: | -4.80 |
P/E: | -1.300 |
Earnings Date: | Jul 10, 2024 |
SharesOutstanding: | 40.05 mill |
Avg Daily Volume: | 0.528 mill |
RATING 2024-04-19 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Neutral | |
P/E: | Neutral | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -1.300 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.04x |
Company: PE -1.300 | industry: PE 33.06 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.179 (-102.86%) $-6.44 |
Date: 2024-04-19 |
Expected Trading Range (DAY) |
---|
$ 6.02 - 6.50 ( +/- 3.82%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-08 | Clemmer James C | Buy | 10 000 | Common Stock |
2024-02-29 | Trowbridge Stephen A | Buy | 1 927 | Common Stock |
2023-07-19 | Trowbridge Stephen A | Buy | 19 354 | Common Stock |
2023-07-19 | Trowbridge Stephen A | Sell | 6 975 | Common Stock |
2023-07-19 | Trowbridge Stephen A | Sell | 30 242 | Performance Right |
INSIDER POWER |
---|
44.86 |
Last 99 transactions |
Buy: 1 280 257 | Sell: 463 344 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $6.26 (2.29% ) |
Volume | 0.472 mill |
Avg. Vol. | 0.528 mill |
% of Avg. Vol | 89.48 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $6.16 | N/A | Active |
---|
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.